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tember 10, 2013.he goal of this research was to assess the prognostic value of proenkephalin (PENK) levels in acute myocardial
infarction (AMI) by using N-terminal pro–B-type natriuretic peptide and Global Registry of Acute Coronary Events
(GRACE) scores as comparators and to identify levels that might be valuable in clinical decision making.Background PENK is a stable analyte of labile enkephalins. Few biomarkers predict recurrent AMI.Methods We measured PENK in 1,141 patients (820 male subjects; mean age 66.2  12.8 years) with AMI. Endpoints were
major adverse events (composite of death, myocardial infarction [MI], and heart failure [HF] hospitalization) and
recurrent MI at 2 years. GRACE scoring was used for comparisons with PENK for the death and/or MI endpoint
at 6 months.Results During follow-up, 139 patients died, and there were 112 HF hospitalizations and 149 recurrent AMIs. PENK levels
were highest on admission and were related to estimated glomerular ﬁltration rate, left ventricular wall motion
index, sex, blood pressure, and age. Multivariable Cox regression models found that the PENK level was a predictor
of major adverse events (hazard ratio [HR]: 1.52 [95% conﬁdence interval (CI): 1.19 to 1.94]), death and/or AMI
(HR: 1.76 [95% CI: 1.34 to 2.30]), and death and/or HF (HR: 1.67 [95% CI: 1.24 to 2.25]) (all comparisons
p < 0.001), as well as recurrent AMI (HR: 1.43 [95% CI: 1.07 to 1.91]; p < 0.01). PENK levels were independent
predictors of 6-month death and/or MI compared with GRACE scores. PENK-adjusted GRACE scores reclassiﬁed
patients signiﬁcantly (overall category-free net reclassiﬁcation improvement [>0] of 21.9 [95% CI: 4.5 to 39.4];
p < 0.014). PENK levels <48.3 pmol/l and >91 pmol/l detected low- and high-risk patients, respectively.Conclusions PENK levels reﬂect cardiorenal status post-AMI and are prognostic for death, recurrent AMI, or HF. Cutoff values
deﬁne low- and high-risk groups and improve risk prediction of GRACE scores. (J Am Coll Cardiol 2014;63:280–9)
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revised manuscript received September 8, 2013,regulation (1). The distribution of preproenkephalin A and
proenkephalin (PENK) is widespread, including in the
nervous system, adrenal medulla, and immune system, and
enkephalins are coreleased from nerve terminals with cate-
cholamines. In the heart, enkephalins are secreted by both
myocytes (2) and nonmyocytes (3), and they may have an
autocrine/paracrine effect, mainly on delta receptors.
Activation of opioid receptors (OPRs) have a predomi-
nantly depressor effect (causing hypotension and brady-
cardia) via central and peripheral mu and delta receptors, as
well as inhibition of norepinephrine release and sympathetic
vasoconstriction (4). OPR activation attenuates the beta-
adrenergic receptor-mediated positive inotropic effect and
the increase in cyclic adenosine monophosphate, but also has
an independent, direct, negatively inotropic effect (5).
Administration of a delta OPR antagonist in dogs with
experimental heart failure (HF) increased blood pressure,
cardiac output, and blood ﬂow to kidney, heart, splanchnic
Abbreviations
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281bed, and skeletal muscle (6). The density of delta and
other OPRs, although widely distributed, is highest in the
kidney (7).
Conversely, delta receptors have also been implicated in
ischemic pre-conditioning, although effects may be depen-
dent on dose and duration of ischemia (8,9). Met-
enkephalin is also a ligand for the widely distributed
opioid growth (or zeta) receptor, which maintains a tonic
inhibitory effect on cell proliferation via cyclin-dependent
inhibitory kinase (p16, p21) pathways (10) and can inhi-
bit ventricular deoxyribonucleic acid synthesis (11).
Manipulation of PENK levels may affect apoptosis, and
PENK associates with histone deacetylase in a transcrip-
tional repression complex that controls pro-apoptosis (12).
Acute stress such as that seen in acute myocardial
infarction (AMI) (13) activates a number of neurohormones,
including the PENK and vasopressin systems. Although
previous studies on met-enkephalin in AMI demonstrated
no change over 4 days (14), interpretation may have been
hampered by the short half-life of met-enkephalin. Recently,
an assay for stable PENK was developed (15), and we have
investigated the utility of this marker compared with existing
risk stratiﬁcation techniques (N-terminal pro–B-type natri-
uretic peptide [NT-proBNP] and risk scores) in AMI.
Biomarkers such as NT-proBNP (16) show greatest asso-
ciation with risk of death and HF post-AMI but are less
useful for predicting the endpoint of readmission with AMI
(recurrent [re-]AMI), justifying a need for improved pre-
diction of this endpoint.Methods
Study population. We studied 1,141 ST-segment eleva-
tion myocardial infarction and non–ST-segment elevation
myocardial infarction (NSTEMI) patients admitted to
University Hospitals of Leicester NHS Trust between
August 2004 and April 2007, predominantly on weekdays
(9 AM to 4 PM). NSTEMI patients were recruited when
a positive troponin result was observed. This observational
cohort study complied with the Declaration of Helsinki
and was approved by the local ethics committee; written
informed consent was obtained from patients.
AMI was diagnosed if a patient had a cardiac troponin I
level above the 99th percentile with at least 1 of the
following: chest pain lasting >20 min or diagnostic serial
electrocardiographic changes consisting of new pathological
Q waves or ST-segment and T-wave changes (17). Patients
with known malignancy, renal replacement therapy, or
surgery in the previous month were excluded. Estimated
glomerular ﬁltration rate (eGFR) was calculated from the
simpliﬁed Modiﬁcation of Diet in Renal Disease formula
(18). All patients received standard medical treatment and
revascularization at the discretion of the attending physician.
Plasma samples. Blood samples (anticoagulated with eth-
ylenediaminetetraacetic acid and aprotinin) were drawn after
15 min of bed rest, immediately after diagnosis, and within36 h of symptom onset (mean 
SEM 20.75  0.35 h). Plasma
was stored at –80C until assayed
in a single batch for blinded
determination of plasma PENK
and NT-proBNP.
Echocardiography. Transthor-
acic echocardiography was per-
formed in 895 (78.4%) patients
during the index admission, using
either a Sonos 5500 or IE 33
instrument (Philips Medical Sys-
tems, Reigate, United Kingdom).
A 16-segment left ventricular wall
motion index score was per-
formed based on the American
Society of Echocardiography
method (19). In suitable patients,
left ventricular ejection fraction
was calculated using the biplane
method of discs formula. Left
ventricular systolic dysfunction
(LVSD) was deﬁned as either
a left ventricular ejection fraction <40% or a left ventricular
wall motion index >1.8.
GRACE scoring. Based on an international observational
database of patients with acute coronary syndromes, Global
Registry of Acute Coronary Events (GRACE) scores can be
calculated on initial presentation to predict in-hospital
mortality (20) or for 6-month major adverse cardiac events
(MACE), deﬁned as death and/or re–myocardial infarction
(MI) (21). We used GRACE scores on discharge for
comparison with 6-month death and/or re-AMI.
Biomarker assays. The Centaur cTnI Ultra immunoassay
(Siemens Healthcare Diagnostics, Deerﬁeld, Illinois) was
used to measure troponin I, which has a coefﬁcient of
variation of 10% at 0.03 mg/l with a 99th percentile of 0.04
mg/l. The NT-proBNP assay was based on a noncompetitive
assay, as previously published (16). An assay for stable
PENK (amino acids 119 to 159 of proenkephalin A) has
been previously reported in detail (15) and was modiﬁed as
follows: in brief, 2 mouse monoclonal anti-PENK anti-
bodies were developed by immunization with PENK
peptide (amino acids 119 to 159 of proenkephalin A). One
antibody (2 mg) was used to coat polystyrene tubes. The
other antibody labeled with methylacridinium ester served
as the detector antibody. Standards (PENK peptide; amino
acids 119 to 159 of proenkephalin A) and samples (50 ml)
were incubated in tubes with the detector antibody (150 ml).
After equilibration, the tubes were washed, and bound
chemiluminescence was detected with a luminometer
(LB952T/16, Berthold Technologies GmbH & Co.,
Wildbad, Germany). The lower detection limit of the
immunoassay was 5.5 pmol/l. Intra-assay and interassay
coefﬁcients of variation were 6.4% and 9.5% at 50 pmol/l,
and 4.0% and 6.5% at 150 pmol/l, respectively. The mean 
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282SEM normal range was 46.6  0.21 pmol/l, with a median
of 45 (range: 9 to 518) pmol/l.
Endpoints. The primary composite endpoint was MACE,
including all-cause mortality, HF hospitalization, or re-
AMI, which were evaluated within 2 years. Hospitaliza-
tion for HF was deﬁned as a hospital readmission for which
HF was the primary reason requiring treatment with high-
dose diuretics, inotropes, or intravenous nitrate. Recurrent
AMI was diagnosed using the universal deﬁnition (17).
Secondary endpoints were composites of death and/or re-
AMI and death and/or HF readmission, and re-AMI
individually. The endpoint of death and/or re-AMI at
6 months was used in analyses involving the GRACE
score because this time point was used in development of
the risk score. Endpoints were obtained by reviewingTable 1 Characteristics of the 1,141 AMI Patients According to PEN
All
(N ¼ 1,141)
1
(<39.9 pmol/l;
n ¼ 285)
(
PENK (pmol/l) 71.1  52.9 30.9  6.1
NT-proBNP (pmol/l) 1,850  2,109 998  1,162
Demographics
Age (yrs) 66.2  12.8 60.0  10.6
Male 820 (72) 243 (85)
STEMI 548 (48) 148 (52)
History
MI 251 (22.0) 40 (14)
Angina pectoris 228 (20) 34 (12)
Heart failure 46 (4) 3 (1)
Hypertension 592 (52) 116 (41)
Diabetes mellitus 262 (23) 51 (18)
Killip class >1 419 (40) 60 (26)
Glucose (mmol/l) 8.9  4.2 8.5  3.8
Troponin I (mg/l) 13.1  25.8 12.9  25.4
eGFR (ml/min/1.73 m2) 65.6  20.1 76.7  15.7
Risk markers on discharge
Echocardiographic LVSD (n ¼ 893)
LV wall motion index 1.47  0.42 1.41  0.40
LV ejection fraction 42.1  14.5 45.5  12.5
GRACE score 120  33 103  26
Treatment
Aspirin 957 (84) 255 (90)
Beta-blocker 911 (80) 246 (87)
ACE inhibitor or ARB 934 (82) 246 (87)
Statin 992 (87) 266 (94)
Revascularization 306 (27) 77 (27)
Endpoints (2 yrs)
MACE 323 (28) 36 (13)
Death 139 (12) 9 (3)
Nonfatal MACE 230 (20) 32 (11)
Heart failure 112 (18) 12 (4)
Re-AMI 149 (13) 21 (7)
Values are mean  SD or n (%). p values are quoted for the Kruskal-Wallis or chi-square tests for conti
ACE ¼ angiotensin-converting enzyme; AMI ¼ acute myocardial infarction; ARB ¼ angiotensin 2 recept
Events; LV ¼ left ventricular; LVSD ¼ left ventricular systolic dysfunction; MACE ¼ major adverse cardiac
proenkephalin; Re- ¼ recurrent; STEMI ¼ ST-segment elevation myocardial infarction.the local hospital databases and the Ofﬁce of National
Statistics Registry and by telephone calls to patients, and
these data were veriﬁed by reviewing medical records. We
achieved 100% follow-up.
Statistical analysis. Statistical analyses were performed
using SPSS version 20 (IBM SPSS Statistics, IBM
Corporation, Armonk, New York) and Stata version 12.1
(Stata Corp., College Station, Texas). Assuming an event
rate of 15% and that the covariates predict up to 30% of the
variance of the biomarker, a sample size of 609 patients
would be powered (90% at p < 0.05) to detect a hazard ratio
(HR) of the biomarker of 1.5, using the command stpower
cox in Stata 12.1. All biomarker levels were log10 trans-
formed. HRs for these refer to 1 SD increment of the log10
transformed biomarker. GRACE scores were used as theK Quartiles on Admission
PENK Quartiles
p Value
2
40.0–55.5 pmol/l;
n ¼ 286)
3
(55.6–83.2 pmol/l;
n ¼ 285)
4
(>83.3 pmol/l;
n ¼ 285)
47.3  4.3 66.9  7.8 139.1  65.6 <0.0005
1,268  1,642 1,713  1,822 3,419  2,629 <0.0005
61.8  11.6 67.6  12.4 75.5  10.4 <0.0005
229 (80) 202 (71) 145 (51) <0.001
140 (49) 134 (47) 120 (42) NS
51 (18) 63 (22) 97 (34) <0.001
43 (15) 69 (24) 77 (27) <0.001
9 (3) 6 (2) 23 (8) <0.001
140 (49) 151 (53) 185 (65) <0.001
66 (23) 63 (22) 86 (30) <0.007
78 (29) 119 (43) 167 (61) <0.001
8.6  3.6 8.1  3.3 10.3  5.7 <0.0005
13.1  26.2 14.6  28.5 11.7  22.9 NS
73.3  17.4 65.2  16.4 47.4  16.9 <0.0005
1.40  0.39 1.49  0.41 1.58  0.44 <0.0005
41.7  14.8 42.2  14.3 38.8  15.7 <0.0005
108  28 122  30 144  30 <0.0005
243 (85) 228 (80) 228 (80) <0.002
237 (83) 223 (78) 207 (73) <0.001
243 (85) 235 (82) 210 (74) <0.001
263 (92) 252 (88) 214 (75) <0.001
87 (30) 77 (27) 65 (27) NS
51 (18) 81 (28) 155 (54) <0.001
11 (4) 28 (10) 91 (32) <0.001
45 (16) 61 (21) 92 (32) <0.001
18 (6) 30 (10) 52 (18) <0.001
32 (11) 42 (15) 54 (19) <0.001
nuous or categorical variables, respectively.
or blocker; eGFR ¼ estimated glomerular ﬁltration rate; GRACE ¼ Global Registry of Acute Coronary
events; MI ¼ myocardial infarction; NT-proBNP ¼ N-terminal pro–B-type natriuretic peptide; PENK ¼
Table 2
Univariate General Linear Model Showing
Independent Predictors of PENK Levels
F Statistic p Value
eGFR 151.195 0.000
Age 16.504 0.000
Wall motion score index 11.399 0.001
Female 11.125 0.001
Diastolic blood pressure 7.048 0.008
History of diabetes 3.545 NS
History of IHD 2.058 NS
Heart rate .146 NS
History of hypertension .005 NS
Adjusted R2 0.41 <0.0005
IHD ¼ ischemic heart disease; other abbreviations as in Table 1.
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283original scores. In comparisons of continuous variables
between PENK quartiles, the Kruskal-Wallis test was used
because the data were not normally distributed. Chi-square
tests were used for categorical variables. Independent
predictors of PENK levels were assessed using univariate
general linear models. To assess the prognostic value of the
biomarkers, a base model was generated using Cox survival
analysis, which included variables that were signiﬁcantly
(p < 0.10) associated with any of the study endpoints on
univariable analysis (age, sex, history of ischemic heart
disease, hypertension or diabetes, Killip class, eGFR, echo-
cardiographic evidence of systolic dysfunction, therapies
including in-hospital revascularization, and biomarkers [log
troponin I and log NT-proBNP]). PENK was added to this
base model to evaluate its relative prognostic value, with all
variables entered simultaneously. A second comparative Cox
model was used to assess the relative prognostic power ofFigure 1 Proﬁle of Plasma PENK During the 5 Days After AMI
Values are given for those with major adverse cardiac events (MACE) (red) or
without MACE (green) at 2 years. Boxes represent interquartile ranges, with the
median marked. Whiskers represent 1.5 times the interquartile range. AMI ¼
acute myocardial infarction; PENK ¼ proenkephalin.these biomarkers and the GRACE score. The additional
prognostic value of PENK to the GRACE score was eval-
uated by using reclassiﬁcation analysis with calculation of
category-free net reclassiﬁcation improvement (NRI) as
described by Pencina et al. (22). We constructed classiﬁca-
tion trees by using chi-square Automatic Interaction
Detection (analysis performed by using SPSS), which
chooses at each step the biomarker that has the strongest
interaction with the dependent variable.Results
Patient characteristics. The characteristics of the study
population according to PENK quartiles are shown in
Table 1. Patients with higher PENK levels were older; were
female; had a history of hypertension, ischemic heart dis-
ease, diabetes, and HF; and had higher GRACE scores and
NT-proBNP levels. They also had more impaired cardiac
and renal function. Revascularization frequencies were
similar between PENK quartiles.
Correlation analysis. Spearman analysis (rs) revealed that
PENK was signiﬁcantly correlated with age (0.488), eGFR
(–0.583), heart rate (0.108), diastolic blood pressure (–0.196),
glucose (0.107), NT-proBNP (0.406), and ejection fraction
(–0.173) (all p < 0.0005). PENK was not correlated with
troponin or peak creatine kinase levels and was weakly
correlated with time from symptom onset (rs ¼ –0.068,
p ¼ 0.023).
A univariate general linear model indicated the following
independent predictors of PENK level, in descending order
according to variance accounted for in the model (Table 2):
eGFR, age, left ventricular wall motion score, female sex,Figure 2
Cumulative Incidence of MACE According to
PENK Quartiles
Cumulative incidence plot of MACE according to PENK quartiles. Abbreviations as
in Figure 1.
Table 3 Cox Regression Analysis for MACE at 2 Years Post-AMI
Univariable p Value Multivariable Model 1 p Value Multivariable Model 2 p Value
Age (yrs) 1.05 (1.04–1.06) 0.000 1.04 (1.02–1.06) 0.001 1.03 (1.01–1.05) 0.001
Male 0.63 (0.50–0.79) 0.000 1.08 (0.74–1.58) NS 1.15 (0.79–1.69) NS
ST-segment elevation 1.09 (0.88–1.36) NS 1.91 (1.25–2.91) 0.003 1.73 (1.13–2.65) 0.012
Killip class >1 2.68 (2.12–3.37) 0.000 1.56 (1.07–2.28) 0.022 1.40 (0.95–2.06) NS
eGFR (ml/min/1.73 m2) 0.97 (0.96–0.98) 0.000 0.99 (0.98–1.00) NS 1.00 (0.99–1.01) NS
Heart rate (beats/min) 1.01 (1.01–1.01) 0.000 0.99 (0.99–1.01) NS 0.99 (0.99–1.00) NS
SBP (mm Hg) 0.99 (0.99–1.00) 0.05 0.99 (0.99–1.00) NS 0.99 (0.99–1.00) NS
LVSD (echo) 2.24 (1.74–2.88) 0.000 1.44 (1.00–2.07) 0.048 1.50 (1.04–2.16) 0.028
History
Ischemic heart disease 1.52 (1.22–1.90) 0.000 1.02 (0.69–1.48) NS 0.97 (0.66–1.42) NS
Hypertension 1.64 (1.31–2.05) 0.000 0.87 (0.59–1.27) NS 0.88 (0.60–1.29) NS
Diabetes 1.55 (1.22–1.96) 0.000 1.36 (0.93–1.99) NS 1.31 (0.89–1.92) NS
Treatment
Revascularization 1.44 (1.14–1.82) 0.002 1.89 (1.25–2.84) 0.002 1.91 (1.27–2.88) 0.002
Aspirin 0.57 (0.44–0.75) 0.000 0.78 (0.53–1.16) NS 0.70 (0.47–1.05) NS
Beta-blockers 0.52 (0.41–0.66) 0.000 0.98 (0.65–1.47) NS 0.89 (0.59–1.35) NS
ACE inhibitor/ARB 0.55 (0.43–0.71) 0.000 0.63 (0.41–0.98) 0.040 0.70 (0.45–1.09) NS
Statins 0.40 (0.31–0.52) 0.000 0.78 (0.47–1.28) NS 0.86 (0.52–1.43) NS
Diuretics 2.36 (1.89–2.94) 0.000 2.15 (1.48–3.13) 0.000 2.04 (1.41–2.96) 0.000
Biomarkers
Log troponin (mg/l) 1.11 (0.99–1.26) NS 1.10 (0.85–1.42) NS 1.11 (0.92–1.35) NS
Log NTproBNP (pmol/l) 1.92 (1.64–2.24) 0.000 1.14 (0.94–1.38) NS 1.04 (0.80–1.34) NS
Log PENK (pmol/l) 1.98 (1.80–2.19) 0.000 1.52 (1.19–1.94) 0.001
C statistic 0.795 (0.755–0.834) 0.810 (0.772–0.847) 0.031
PENK quartiles
1 Reference 0.000 Reference 0.000
2 1.35 (0.88–2.07) NS 1.22 (0.75–1.99) NS
3 2.28 (1.54–3.38) 0.000 1.66 (1.05–2.64) 0.032
4 5.44 (3.78–7.82) 0.000 2.78 (1.71–4.51) 0.000
Values are hazard ratio (95% conﬁdence interval). Multivariable analysis results are reported for model 1, which included variables and biomarkers (except PENK) that were signiﬁcant on univariable analysis.
Multivariable model 2 used the variables in model 1 with the addition of PENK as a continuous variable. Hazard ratios for PENK entered as quartiles are reported at the bottom of the table.
NT-proBNP ¼ N-terminal pro–B-type natriuretic peptide; SBP ¼ systolic blood pressure; other abbreviations as in Table 1.
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284and diastolic blood pressure. eGFR accounted for the
majority of the variance (27%).
Day curves for PENK. Sequential plasma samples for 5
days were available for 107 patients, 28 of whom had
MACE within 2 years. Figure 1 demonstrates the plasma
proﬁle along with a general linear model with repeated
measures that shows signiﬁcant changes in PENK over
time (p < 0.001) and higher levels in those with MACE
(p < 0.01). In post-hoc testing, PENK levels on day 1
were higher than all other days (p < 0.001, Bonferroni-
corrected for multiple comparisons). PENK levels on days
2 to 5 were similar. There was no statistically signiﬁcant
interaction of the changes of PENK with time and MACE.
Survival analysis. During a 2-year follow-up, there were
139 deaths, 112 HF hospitalizations, and 149 re-AMIs.
Patients with elevated PENK levels (log10 transformed and
expressed as a continuous variable) had more MACE,
deaths, and rehospitalizations with HF or re-AMI
(Table 1). Figure 2 illustrates the cumulative incidence of
MACE according to PENK quartiles (p < 0.0005). Table 3
reports the univariable HRs of various factors that affected
the outcome of MACE at 2 years. In multivariable analysis
for predicting MACE at 2 years, the base model(multivariable model 1 in Table 3) included the following
independent predictors: age, ST-segment elevation on elec-
trocardiography, Killip class >1, LVSD, revascularization,
and treatment with angiotensin-converting enzyme inhibi-
tors/angiotensin receptor blockers and diuretics. Addition of
PENK to the base model (model 2 in Table 3) retained the
following predictors: age, ST-segment elevation on electro-
cardiography, LVSD, revascularization, treatment with
diuretics, and log PENK (HR: 1.52 [95% conﬁdence interval
(CI): 1.19 to 1.94]; p < 0.001). The C statistic improved
signiﬁcantly from 0.795 to 0.810 (p¼ 0.031) (Table 3). Tests
for multicollinearity revealed variance inﬂation factors
of <2.1 for all variables, suggesting that multicollinearity did
not affect the analysis.
Entering PENK as quartiles to the MACE multivariable
model (Table 3) revealed that the top PENK quartile had
an HR of 2.78 (95% CI: 1.71 to 4.51) compared with the
lowest quartile (p < 0.0005).
Category-free reclassiﬁcation analysis was used as
described by Pencina et al. (22) to calculate the NRI (>0)
so that no arbitrary cutoff probabilities are chosen for
analysis. The models were well calibrated as indicated by
nonsigniﬁcant Hosmer-Lemeshow goodness-of-ﬁt tests
Table 4 Cox Regression Analysis for Death and/or MI at 2 Years Post-AMI
Univariable p Value Multivariable Model 1 p Value Multivariable Model 2 p Value
Age (yrs) 1.05 (1.04–1.06) 0.000 1.04 (1.02–1.07) 0.000 1.04 (1.02–1.06) 0.000
Male 0.66 (0.51–0.85) 0.001 1.08 (0.70–1.65) NS 1.15 (0.74–1.78) NS
ST-segment elevation 1.04 (0.81–1.32) NS 1.47 (0.90–2.38) NS 1.35 (0.83–2.19) NS
Killip class >1 2.09 (1.62–2.70) 0.000 1.24 (0.81–1.91) NS 1.07 (0.69–1.66) NS
eGFR (ml/min/1.73 m2) 0.97 (0.96–0.98) 0.000 0.99 (0.98–1.01) NS 1.00 (0.99–1.02) NS
Heart rate (beats/min) 1.01 (1.00–1.01) 0.001 1.00 (0.99–1.01) NS 1.00 (0.99–1.01) NS
SBP (mm Hg) 0.99 (0.99–1.00) 0.050 1.00 (0.99–1.01) NS 1.00 (0.99–1.01) NS
LVSD (echo) 2.14 (1.61–2.83) 0.000 1.28 (0.85–1.91) NS 1.35 (0.90–2.02) NS
History
Ischemic heart disease 1.60 (1.26–2.05) 0.000 1.27 (0.84–1.94) NS 1.19 (0.78–1.83) NS
Hypertension 1.55 (1.20–1.99) 0.001 0.88 (0.57–1.34) NS 0.89 (0.58–1.37) NS
Diabetes 1.54 (1.18–1.99) 0.001 1.41 (0.93–2.15) NS 1.34 (0.88–2.05) NS
Treatment
Revascularization 1.65 (1.28–2.13) 0.000 2.09 (1.35–3.25) 0.001 2.19 (1.41–3.40) 0.001
Aspirin 0.64 (0.48–0.87) 0.004 0.96 (0.60–1.52) NS 0.87 (0.54–1.39) NS
Beta-blockers 0.59 (0.45–0.77) 0.000 1.12 (0.71–1.79) NS 0.99 (0.62–1.57) NS
ACE inhibitor/ARB 0.49 (0.37–0.64) 0.000 0.70 (0.43–1.14) NS 0.80 (0.49–1.31) NS
Statins 0.38 (0.29–0.51) 0.000 0.65 (0.38–1.13) NS 0.72 (0.42–1.25) NS
Diuretics 1.84 (1.43–2.36) 0.000 1.61 (1.05–2.46) 0.028 1.48 (0.97–2.26) NS
Biomarkers
Log troponin (mg/l) 1.05 (0.92–1.21) NS 1.15 (0.92–1.44) NS 1.11 (0.89–1.38) NS
Log NTproBNP (pmol/l) 1.82 (1.53–2.16) 0.000 1.02 (0.77–1.35) NS 0.94 (0.71–1.24) NS
Log PENK (pmol/l) 1.94 (1.74-2.16) 0.000 1.76 (1.34–2.30) 0.000
C statistic 0.788 (0.748–0.828) 0.802 (0.763–0.840) 0.11
PENK quartiles
1 Reference Reference
2 1.40 (0.86–2.27) NS 1.31 (0.62–2.74) NS
3 2.35 (1.50–3.67) 0.000 1.62 (0.80–3.28) NS
4 5.46 (3.61–8.28) 0.000 2.50 (1.17–5.36) 0.01
Values are hazard ratio (95% conﬁdence interval). Multivariable analysis results are reported for model 1, which included variables and biomarkers (except PENK) that were signiﬁcant on univariable analysis.
Multivariable model 2 used the variables in model 1 with the addition of PENK. Hazard ratios for PENK entered as quartiles are reported at the bottom of the table.
Abbreviations as in Tables 1 and 3.
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285(while acknowledging the limitations of this test) and
visualization of the calibration plots. The NRI in those
without the MACE endpoint was 13.0 (95% CI: 4.8 to
21.2; p ¼ 0.002), indicating that 13% of those without
MACE who were deemed high risk in model 1 had been
down-classiﬁed after addition of PENK to the model. In
those with the endpoint, NRI was 18.1 (95% CI: 5.1 to
31.1; p ¼ 0.007), indicating that 18.1% of those with
MACE who were deemed low risk in model 1 had been
up-classiﬁed after addition of PENK to the model. Overall
NRI (>0) was 31.1 (95% CI: 15.7 to 46.4; p < 0.0005),
suggesting that PENK improved the risk stratiﬁcation of
the base model.
In other models for prediction of the secondary composite
endpoints of death and/or re-AMI (Table 4) and death
and/or HF readmission (Table 5), PENK remained an
independent predictor (death/MI HR: 1.76 [95% CI: 1.34
to 2.30]; death/HF HR: 1.67 [95% CI: 1.24 to 2.25);
p < 0.001 for both) with corresponding increases in C
statistic (to 0.802 [p ¼ 0.11] and 0.799 (p ¼ 0.041],
respectively). The HR of the top quartile of PENK was
signiﬁcantly higher than the lowest reference quartile for
both composite endpoints.Table 6 reports the univariable and multivariable HRs
for the endpoint of re-AMI at 2 years. The base model
(model 1 in Table 6) included the following signiﬁcant
predictors: age, ST-segment elevation, revascularization,
and diuretic treatment. Addition of PENK to this model
revealed PENK as a predictor (HR: 1.43 [95% CI: 1.07 to
1.91]; p < 0.01) together with ST-segment elevation and
revascularization. The C statistic improved from 0.712 to
0.735 (p ¼ 0.004) after the addition of PENK.
Comparison with GRACE scores. The widely used
GRACE risk score (21) was originally derived for prediction
of death and/or MI at 6 months. GRACE scores and the
biomarkers NT-proBNP and PENK were predictors of
MACE, death and/or MI, and death and/or HF in uni-
variable analysis (Table 7). In multivariable analysis for
MACE and death and/or MI at 6 months, GRACE score
and PENK remained predictors, whereas NT-proBNP was
only retained for the death and/or HF model.
For the 6-month death/MI endpoint, the C statistic only
increased from 0.693 (95% CI: 0.647 to 0.739) for
GRACE scoring to 0.734 (95% CI: 0.691 to 0.778) with
the addition of PENK (p < 0.0047). No further im-
provement in the area under the curve was observed with
Table 5 Cox Regression Analysis for Death and/or Heart Failure at 2 Years Post-AMI
Univariable p Value Multivariable Model 1 p Value Multivariable Model 2 p Value
Age (yrs) 1.07 (1.06–1.09) 0.000 1.03 (1.00–1.06) 0.032 1.03 (1.00–1.05) 0.050
Male 0.51 (0.39–0.66) 0.000 1.19 (0.76–1.89) NS 1.27 (0.79–2.01) NS
ST-segment elevation 0.99 (0.77–1.30) NS 1.33 (0.79–2.22) NS 1.21 (0.72–2.03) NS
Killip class >1 3.78 (2.81–5.08) 0.000 2.02 (1.24–3.30) 0.005 1.75 (1.06–2.87) 0.027
eGFR (ml/min/1.73 m2) 0.96 (0.95–0.97) 0.000 0.98 (0.97–0.99) 0.003 0.99 (0.98–1.01) NS
Heart rate (beats/min) 1.01 (1.01–1.02) 0.000 1.00 (0.99–1.00) NS 1.00 (0.99–1.00) NS
SBP (mm Hg) 0.99 (0.98–0.99) 0.004 0.99 (0.98–0.99) 0.010 0.99 (0.98–0.99) 0.006
LVSD (echo) 3.07 (2.25–4.18) 0.000 1.62 (1.04–2.54) 0.033 1.73 (1.10–2.71) 0.017
History
Ischemic heart disease 1.57 (1.21–2.04) 0.001 0.94 (0.60–1.49) NS 0.88 (0.56–1.40) NS
Hypertension 1.69 (1.29–2.22) 0.000 0.73 (0.46–1.16) NS 0.74 (0.47–1.18) NS
Diabetes 1.57 (1.19–2.09) 0.002 1.33 (0.84–2.10) NS 1.25 (0.79–1.97) NS
Treatment
Revascularization 1.02 (0.76–1.36) NS 1.28 (0.75–2.19) NS 1.31 (0.76–2.26) NS
Aspirin 0.50 (0.37–0.68) 0.000 0.69 (0.43–1.10) NS 0.61 (0.38–0.99) 0.044
Beta-blockers 0.36 (0.27–0.47) 0.000 0.81 (0.51–1.29) NS 0.74 (0.46–1.19) NS
ACE inhibitor/ARB 0.47 (0.36–0.63) 0.000 0.70 (0.42–1.17) NS 0.79 (0.47–1.32) NS
Statins 0.28 (0.21–0.38) 0.000 0.66 (0.38–1.16) NS 0.73 (0.41–1.29) NS
Diuretics 3.17 (2.43–4.11) 0.000 2.32 (1.50–3.60) 0.000 2.24 (1.44–3.47) 0.000
Biomarkers
Log troponin (μg/l) 1.15 (0.99–1.33) 0.051 1.13 (0.89–1.43) NS 1.11 (0.87–1.40) NS
Log NT-proBNP (pmol/l) 3.20 (2.56–4.00) 0.000 1.49 (1.04–2.15) 0.032 1.40 (0.97–2.01) NS
Log PENK (pmol/l) 2.35 (2.09–2.64) 0.000 1.67 (1.24–2.25) 0.001
C statistic 0.785 (0.745–0.826) 0.799 (0.760–0.838) 0.041
PENK quartiles
1 Reference Reference
2 1.24 (0.69–2.26) NS 1.22 (0.45–3.18) NS
3 2.70 (1.60–4.57) 0.000 1.66 (0.68–3.94) NS
4 7.98 (4.93–12.92) 0.000 2.51 (1.01–6.30) 0.05
Values are hazard ratio (95% conﬁdence interval). Multivariable analysis results are reported for model 1, which included variables and biomarkers (except PENK) that were signiﬁcant on univariable analysis.
Multivariable model 2 used the variables in model 1 with the addition of PENK. Hazard ratios for PENK entered as quartiles are reported at the bottom of the table.
Abbreviations as in Tables 1 and 3.
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286the addition of NT-proBNP (0.734, 95% CI: 0.691 to
0.778; p ¼ NS).
Figure 3 shows the reclassiﬁcation plot as proposed by
Steyerberg et al. (23), with probabilities of events by using
GRACE scoring alone plotted against probabilities of events
by using PENK-adjusted GRACE scores. Probabilities
adjusted by using PENK in those with adverse outcomes
were up-classiﬁed (i.e., above the diagonal in Fig. 2).
Hosmer-Lemeshow goodness-of-ﬁt tests indicated good
calibration of models. Category-free reclassiﬁcation analysis
demonstrated that the NRI (>0) in those without the
endpoint of death and/or MI at 6 months was –1.5 (95% CI:
–8.3 to 5.2; p ¼ NS) and in those with the endpoint, it
was 23.5 (95% CI: 7.4 to 39.5; p < 0.004), with an overall
NRI (>0) of 21.9 (95% CI: 4.5 to 39.4; p < 0.014). These
ﬁndings suggest that PENK improved the risk stratiﬁcation
from GRACE scoring (predominantly from up-classifying
risk in those with death/MI).
For the endpoint of MACE at 6 months, the NRI in those
without MACE was 1.0 (95% CI: –5.9 to 7.9; p ¼ NS) and
in those with the endpoint, it was 26.0 (95% CI: 11.9 to 40.2;
p < 0.000). The overall NRI (>0) was 27.0 (95% CI: 11.3 to
42.8; p < 0.001).Decision tree analysis. To determine optimal cutoff points
for biomarkers, we constructed a decision tree (by using
PENK and NT-proBNP levels and GRACE scores) to
classify patients into survivors or those with endpoints.
For the endpoint of death and/or MI at 6 months, PENK
was selected as the optimal initial classiﬁer (Fig. 4), with
NT-proBNP used at another node. For those with
PENK <48.3 pmol/l, a low-risk group (n ¼ 456 [40% of
the cohort]) was deﬁned with 30 deaths and/or MI events at
6 months. At 30 days, this low-risk group had 12 events,
including 2 deaths. Patients with PENK >91 pmol/l were at
high risk of death and/or MI (18.9% at 30 days, 34.2% at 6
months).
Discussion
In this observational cohort study, we describe the use of
a novel PENK assay for risk stratiﬁcation after AMI,
measuring an analyte that is stable in plasma, unlike previous
assays of labile enkephalins. Analysis of variance suggests that
the major independent factors which inﬂuenced PENK levels
are renal function (eGFR), age, cardiac function (left
ventricular wall motion score index), sex, and diastolic blood
Table 6 Cox Regression Analysis for Re-MI at 2 Years Post-AMI
Univariable p Value Multivariable Model 1 p Value Multivariable Model 2 p Value
Age (yrs) 1.02 (1.01–1.03) 0.004 1.03 (1.00–1.05) 0.035 1.02 (1.00–1.05) NS
Male 0.85 (0.60–1.21) NS
ST-segment elevation 1.15 (0.83–1.58) NS 2.04 (1.23–3.39) 0.006 1.96 (1.19–3.25) 0.009
Killip class >1 1.64 (1.18–2.27) 0.003 0.92 (0.57–1.48) NS 0.83 (0.51–1.36) NS
eGFR (ml/min/1.73 m2) 0.99 (0.98–0.99) 0.016 1.00 (0.99–1.02) NS 1.00 (0.99–1.02) NS
Heart rate (beats/min) 1.00 (0.99–1.01) NS
SBP (mm Hg) 1.00 (0.99–1.01) NS
LVSD (echo) 1.60 (1.12–2.29) 0.010 1.48 (0.94–2.31) NS 1.50 (0.96–2.35) NS
History
Ischemic heart disease 1.73 (1.25–2.39) 0.001 1.33 (0.82–2.13) NS 1.29 (0.80–2.08) NS
Hypertension 1.56 (1.12–2.18) 0.008 1.17 (0.73–1.85) NS 1.15 (0.72–1.83) NS
Diabetes 1.60 (1.13–2.26) 0.008 1.18 (0.73–1.90) NS 1.18 (0.73–1.90) NS
Treatment
Revascularization 1.92 (1.38–2.68) 0.000 2.16 (1.34–3.48) 0.002 2.21 (1.37–3.57) 0.001
Aspirin 0.99 (0.63–1.55) NS
Beta-blockers 1.29 (0.82–2.03) NS
ACE inhibitor/ARB 0.74 (0.50–1.09) NS
Statins 1.03 (0.61–1.76) NS
Diuretics 1.51 (1.07–2.13) 0.018 1.67 (1.03–2.71) 0.038 1.59 (0.98–2.59) NS
Biomarkers
Log troponin (mg/l) 1.01 (0.84–1.20) NS 1.09 (0.86–1.38) NS 1.08 (0.86–1.37) NS
Log NT-proBNP (pmol/l) 1.25 (1.04–1.52) 0.019 1.07 (0.79–1.45) NS 1.02 (0.76–1.38) NS
Log PENK (pmol/l) 1.46 (1.26–1.71) 0.000 1.43 (1.07–1.91) 0.010
C statistic 0.712 (0.667–0.756) 0.735 (0.692–0.778) 0.004
PENK quartiles
1 Reference Reference
2 1.44 (0.83–2.49) NS 1.47 (0.69–3.14) NS
3 1.96 (1.16–3.31) 0.01 1.78 (0.85–3.70) NS
4 3.01 (1.82–4.98) 0.000 2.05 (0.93–4.57) 0.07
Values are hazard ratio (95% conﬁdence interval). Multivariable analysis results are reported for model 1, which included variables and biomarkers (except PENK) that were signiﬁcant on univariable analysis.
Multivariable model 2 used the variables in model 1 with the addition of PENK. Hazard ratios for PENK entered as quartiles are reported at the bottom of the table.
Abbreviations as in Tables 1 and 3.
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no inﬂuence on PENK levels. PENK may therefore closely
integrate the cardiorenal status of an individual, and the
observation that levels peaked on presentation with AMImay
represent an advantage for early risk assessment. Previous
studies such as those from the GRACE investigators (20,21)Table 7
Cox Regression Analysis for Endpoints a
Death and/or HF)
Univariable
MACE
GRACE score 1.02 (1.02–1.03)
Log NT-proBNP (pmol/l) 2.01 (1.66–2.42)
Log PENK (pmol/l) 1.95 (1.74–2.19)
Death and/or MI
GRACE score 1.02 (1.01–1.02)
Log NT-proBNP (pmol/l) 1.87 (1.52–2.31)
Log PENK (pmol/l) 1.91 (1.68–2.17)
Death and/or HF
GRACE score 1.03 (1.02–1.04)
Log NT-proBNP (pmol/l) 3.20 (2.45–4.18)
Log PENK (pmol/l) 2.27 (1.98–2.59)
Values are hazard ratio (95% conﬁdence interval).
HF ¼ heart failure; other abbreviations as in Tables 1 and 3.have emphasized the importance of cardiac and renal function
in determining risk after acute coronary syndromes, which
may explain the prognostic performance of PENK for adverse
events post-AMI. In addition, PENK was associated with
cardiovascular outcomes such as death, re-AMI, and HF
rehospitalization. Existing biomarkers such as NT-proBNPt 6 Months (MACE, Death and/or MI,
p Value Multivariable p Value
0.000 1.01 (1.00–1.02) 0.000
0.000 1.23 (0.99–1.52) NS
0.000 1.56 (1.32–1.83) 0.000
0.000 1.01 (1.00–1.01) 0.016
0.000 1.20 (0.95–1.52) NS
0.000 1.65 (1.38–1.99) 0.000
0.000 1.02 (1.01–1.02) 0.000
0.000 1.72 (1.26–2.34) 0.001
0.000 1.57 (1.29–1.91) 0.000
Figure 3
Up- and Down-Reclassiﬁcation of the Probabilities of
Events in Survivors and Patients With the Endpoint of
Death and/or MI at 6 Months
The Global Registry of Acute Coronary Events (GRACE) score–derived probability of
death/myocardial infarction (MI) in subjects with endpoints (red) has been up-
classiﬁed (above the diagonal line of equivalence) after adjustment by using PENK,
with a small preponderance (1.5%) of those without the endpoint (green) being
up-classiﬁed.
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performance for re-AMI.
The prognostic performance of PENK was conﬁrmed by
using a panel of different tests, including Cox survivalFigure 4 Classiﬁcation Tree for Death/MI at 6 Months
MI ¼ myocardial infarction; NT-proBNP ¼ N-terminal pro–B-type natriuretic peptide;
PENK ¼ proenkephalin.analysis, reclassiﬁcation analysis, and classiﬁcation by using
decision trees. PENK retained its independent predictive
value and demonstrated additional utility to the GRACE
score in reclassiﬁcation analysis, the major effect being on
up-classiﬁcation of those with endpoints. PENK levels were
also prognostic for both short- and long-term adverse events
up to 2 years. Current guidelines recommend that post-
AMI, patients should undergo risk stratiﬁcation so that
appropriate therapy can be instituted (24), as intensiﬁcation
of therapy is especially efﬁcacious in high-risk patients. In
addition, PENK levels <48.3 pmol/l may deﬁne a low-risk
group of patients who potentially could be discharged earlier
from the hospital.
This association of PENK with poor outcomes may reﬂect
a direct link between pathophysiological actions of enkepha-
lins and adverse events. The enkephalins act mainly on delta
OPRs, with a predominantly depressor effect on the cardio-
vascular system (5,6) and on tissue perfusion, including the
kidneys. OPRs are widely distributed, with high concentra-
tions in the kidney (7). In addition, delta OPRs have been
implicated in ischemia pre-conditioning (8,9), although this
effect may be dependent on the duration and concentration of
ischemia. Enkephalins also act on the zeta or opioid growth
receptor, which exerts an antiproliferative or pro-apoptotic
effect (10,11). Our studies suggest a correlation between
PENK (a surrogate of enkephalin levels) and adverse events,
and there may be a causal relationship between enkephalins
and these adverse events. Previous research on heroin addicts
suggest an up-regulation of platelet alpha2-adrenoceptors
(25). An opioid antagonist (naltrexone) suppressed
adrenaline-induced platelet aggregation and alpha2-adreno-
ceptor density. In post-MI patients, it is unknown whether
enkephalins affect the adrenaline-induced platelet aggregation
in vivo. PENK levels were inversely correlated with renal
function, echocardiographic evidence of left ventricular
impairment, and blood pressure. These ﬁndings are hypoth-
esis generating for investigating the effect of OPR antagonists
on MACE and platelet function after reperfusion, when the
beneﬁcial effects of enkephalins on reperfusion injury have
been accrued.
Study limitations. Our ﬁndings are based on a population
from a single center, with 2 admitting hospitals, and should
be veriﬁed in other larger populations. The rate of early
revascularization in our NSTEMI population was low and
may not reﬂect a more contemporary invasive approach of
revascularization within 72 h of presentation. However, it
is unlikely that the relationship of PENK with adverse
events would have been confounded by higher early revas-
cularization rates. Another advantage of a registry-like study
(as opposed to a clinical trial) is that endpoints may not be
affected by investigational therapies. We excluded patients
with unstable angina, some of whom may have been regar-
ded as NSTEMI on more contemporary high-sensitivity
troponin assays; this action may also have affected the
Cox regression analysis models. In addition, we used an in-
house NT-proBNP assay; this assay is well established and
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289correlated well with the Roche NT-proBNP assay (rs ¼
0.90). Reclassiﬁcation analyses have not been fully validated
in the published literature, and signiﬁcance tests need to be
conﬁrmed (26). Prospective studies on the clinical effec-
tiveness of using this biomarker for management strategies,
whether in low- or high-risk groups, need to be performed.
Conclusions
After AMI, circulating PENK levels reﬂect cardiorenal
status and provide prognostic information, over and above
that provided by the GRACE score and the current gold
standard biomarkers NT-proBNP and troponin. The ability
of PENK to predict re-AMI, in addition to mortality and
HF events, may confer clinical utility on this endogenous
opioid in risk stratiﬁcation after AMI.
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